litlas
ログインアカウント作成

Frederick L. Locke

1990–2025 年に発表

175
論文数
31,246
被引用数
61
h 指数
157
i10 指数

被引用数

Frederick L. Locke の年別被引用数1990 年: 被引用 4 件1991 年: 被引用 1 件1992 年: 被引用 4 件1993 年: 被引用 3 件1995 年: 被引用 1 件1996 年: 被引用 1 件1997 年: 被引用 2 件1998 年: 被引用 1 件2001 年: 被引用 3 件2003 年: 被引用 1 件2005 年: 被引用 1 件2006 年: 被引用 2 件2013 年: 被引用 4 件2014 年: 被引用 11 件2015 年: 被引用 5 件2016 年: 被引用 4 件2017 年: 被引用 27 件2018 年: 被引用 184 件2019 年: 被引用 776 件2020 年: 被引用 1,545 件2021 年: 被引用 2,073 件2022 年: 被引用 2,130 件2023 年: 被引用 2,011 件2024 年: 被引用 3,418 件2025 年: 被引用 1,851 件2026 年: 被引用 47 件1994 年は被引用が無いため表示していません1999〜2000 年は被引用が無いため表示していません2002 年は被引用が無いため表示していません2004 年は被引用が無いため表示していません2007〜2012 年は被引用が無いため表示していません

引用元

国・地域

この著者を引用した国・地域の世界地図アメリカ合衆国: 引用元論文 3,444 件、この内訳の 30.6%中国: 引用元論文 1,322 件、この内訳の 11.7%ドイツ: 引用元論文 787 件、この内訳の 7%イギリス: 引用元論文 568 件、この内訳の 5%イタリア: 引用元論文 547 件、この内訳の 4.9%フランス: 引用元論文 509 件、この内訳の 4.5%スペイン: 引用元論文 440 件、この内訳の 3.9%カナダ: 引用元論文 340 件、この内訳の 3%オーストラリア: 引用元論文 286 件、この内訳の 2.5%スイス: 引用元論文 278 件、この内訳の 2.5%オランダ: 引用元論文 257 件、この内訳の 2.3%日本: 引用元論文 186 件、この内訳の 1.7%
0%30.6%その他 20.4%

機関

分野

  • Medicine88.6%
  • Biochemistry, Genetics and Molecular Biology5.1%
  • Immunology and Microbiology4.3%
  • Engineering0.8%
  • Computer Science0.3%
  • Neuroscience0.2%
  • その他0.7%

トピック

  • CAR-T cell therapy research26%
  • Virus-based gene therapy research6%
  • Immune Cell Function and Interaction5.4%
  • Lymphoma Diagnosis and Treatment5.2%
  • Nanowire Synthesis and Applications4.2%
  • Cancer Immunotherapy and Biomarkers4%
  • その他49.2%

共著者

全論文

検索で開く
  1. Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma

    著者: Sattva S. Neelapu, Frederick L. Locke, Nancy L. Bartlett, Lazaros J. Lekakis, David B. Miklos, Caron A. Jacobson, Ira Braunschweig, Olalekan O. Oluwole, Tanya Siddiqi, Yi Lin, John M. Timmerman, Patrick J. Stiff, Jonathan W. Friedberg, Ian W. Flinn, André Goy, Brian T. Hill, Mitchell R. Smith, Abhinav Deol, Umar Farooq, Peter A. McSweeney, Javier Muñoz, Irit Avivi, Januario E. Castro, Jason R. Westin, Julio C. Chávez, Armin Ghobadi, Krishna V. Komanduri, Ronald Levy, Eric D. Jacobsen, Thomas E. Witzig, Patrick M. Reagan, Adrian Bot, John M. Rossi, Lynn Navale, Yizhou Jiang, Jeff Aycock, Meg Elias, David Chang, Jeff Wiezorek, William Y. Go - New England Journal of Medicine 2017 被引用: 5,915

  2. ASTCT Consensus Grading for Cytokine Release Syndrome and Neurologic Toxicity Associated with Immune Effector Cells

    著者: Daniel W. Lee, Bianca Santomasso, Frederick L. Locke, Armin Ghobadi, Cameron J. Turtle, Jennifer N. Brudno, Marcela V. Maus, Jae H. Park, Elena Mead, Steven Z. Pavletic, William Y. Go, Lamis Eldjerou, Rebecca Gardner, Noelle V. Frey, Kevin J. Curran, Karl S. Peggs, Marcelo C. Pasquini, John F. DiPersio, Marcel R.M. van den Brink, Krishna V. Komanduri, Stephan A. Grupp, Sattva S. Neelapu - Biology of Blood and Marrow Transplantation 2018 被引用: 3,445

  3. Axicabtagene Ciloleucel as Second-Line Therapy for Large B-Cell Lymphoma

    著者: Frederick L. Locke, David B. Miklos, Caron A. Jacobson, Miguel‐Angel Perales, Marie José Kersten, Olalekan O. Oluwole, Armin Ghobadi, Aaron P. Rapoport, Joseph P. McGuirk, John M. Pagel, Javier Muñoz, Umar Farooq, Tom van Meerten, Patrick M. Reagan, Anna Sureda, Ian W. Flinn, Peter Vandenberghe, Kevin Song, Michael Dickinson, Monique C. Minnema, Peter A. Riedell, Lori A. Leslie, Sridhar Chaganti, Yin Yang, Simone Filosto, Jina Shah, Marco Schupp, Christina To, Paul Cheng, Leo I. Gordon, Jason R. Westin - New England Journal of Medicine 2021 被引用: 1,520

  4. KTE-X19 CAR T-Cell Therapy in Relapsed or Refractory Mantle-Cell Lymphoma

    著者: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Nöel Milpied, Henry C. Fung, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Lianqing Zheng, John M. Rossi, Rajul K. Jain, Arati V. Rao, Patrick M. Reagan - New England Journal of Medicine 2020 被引用: 1,823

  5. Long-term safety and activity of axicabtagene ciloleucel in refractory large B-cell lymphoma (ZUMA-1): a single-arm, multicentre, phase 1–2 trial

    著者: Frederick L. Locke, Armin Ghobadi, Caron A. Jacobson, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Jeffrey S. Wiezorek, Lynn Navale, Allen Xue, Yizhou Jiang, Adrian Bot, John M. Rossi, Jaeyeon Kim, William Y. Go, Sattva S. Neelapu - The Lancet Oncology 2018 被引用: 2,251

  6. Chimeric antigen receptor T-cell therapy — assessment and management of toxicities

    著者: Sattva S. Neelapu, Sudhakar Tummala, Partow Kebriaei, William G. Wierda, Cristina Gutiérrez, Frederick L. Locke, Krishna V. Komanduri, Yi Lin, Nitin Jain, Naval Daver, Jason R. Westin, Alison Gulbis, Monica Loghin, John de Groot, Sherry Adkins, Suzanne E. Davis, Katayoun Rezvani, Patrick Hwu, Elizabeth J. Shpall - Nature Reviews Clinical Oncology 2017 被引用: 2,380

  7. Standard-of-Care Axicabtagene Ciloleucel for Relapsed or Refractory Large B-Cell Lymphoma: Results From the US Lymphoma CAR T Consortium

    著者: Loretta J. Nastoupil, Michael D. Jain, Lei Feng, Jay Y. Spiegel, Armin Ghobadi, Yi Lin, Saurabh Dahiya, Matthew A. Lunning, Lazaros J. Lekakis, Patrick M. Reagan, Olalekan O. Oluwole, Joseph P. McGuirk, Abhinav Deol, Alison R. Sehgal, André Goy, Brian T. Hill, Khoan Vu, Charalambos Andreadis, Javier Muñoz, Jason R. Westin, Julio C. Chávez, Amanda F. Cashen, N. Nora Bennani, Aaron P. Rapoport, Julie M. Vose, David B. Miklos, Sattva S. Neelapu, Frederick L. Locke - Journal of Clinical Oncology 2020 被引用: 786

  8. Survival with Axicabtagene Ciloleucel in Large B-Cell Lymphoma

    著者: Jason R. Westin, Olalekan O. Oluwole, Marie José Kersten, David B. Miklos, Miguel‐Angel Perales, Armin Ghobadi, Aaron P. Rapoport, Anna Sureda, Caron A. Jacobson, Umar Farooq, Tom van Meerten, Matthew L. Ulrickson, Mahmoud Elsawy, Lori A. Leslie, Sridhar Chaganti, Michael Dickinson, Kathleen Dorritie, Patrick M. Reagan, Joseph P. McGuirk, Kevin Song, Peter A. Riedell, Monique C. Minnema, Yin Yang, Saran Vardhanabhuti, Simone Filosto, Paul Cheng, Shilpa Shahani, Marco Schupp, Christina To, Frederick L. Locke - New England Journal of Medicine 2023 被引用: 410

  9. Unanswered questions following reports of secondary malignancies after CAR-T cell therapy

    著者: Bruce L. Levine, Marcelo C. Pasquini, John E. Connolly, David L. Porter, Michael P. Gustafson, Jaap Jan Boelens, Edwin M. Horwitz, Stephan A. Grupp, Marcela V. Maus, Frederick L. Locke, Fabio Ciceri, Annalisa Ruggeri, John A. Snowden, Helen E. Heslop, Crystal L. Mackall, Carl H. June, Anna M. Sureda, Miguel‐Angel Perales - Nature Medicine 2024 被引用: 196

  10. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

    著者: Kai Rejeski, Ariel Perez Perez, Pierre Sesques, Eva Hoster, Carolina Berger, Liv Jentzsch, Dimitrios Mougiakakos, Lisa Frölich, Josephine Ackermann, Veit Bücklein, Viktoria Blumenberg, Christian Schmidt, Laurent Jallades, Boris Fehse, Christoph Faul, Philipp Karschnia, Oliver Weigert, Martin Dreyling, Frederick L. Locke, Michael von Bergwelt‐Baildon, Andréas Mackensen, Wolfgang Bethge, Francis Ayuk, Emmanuel Bachy, Gilles Salles, Michael D. Jain, Marion Subklewe - Blood 2021 被引用: 441

  11. Tumor burden, inflammation, and product attributes determine outcomes of axicabtagene ciloleucel in large B-cell lymphoma

    著者: Frederick L. Locke, John M. Rossi, Sattva S. Neelapu, Caron A. Jacobson, David B. Miklos, Armin Ghobadi, Olalekan O. Oluwole, Patrick M. Reagan, Lazaros J. Lekakis, Yi Lin, Marika Sherman, Marc Better, William Y. Go, Jeffrey S. Wiezorek, Allen Xue, Adrian Bot - Blood Advances 2020 被引用: 455

  12. Idecabtagene Vicleucel for Relapsed/Refractory Multiple Myeloma: Real-World Experience From the Myeloma CAR T Consortium

    著者: Doris K. Hansen, Surbhi Sidana, Lauren C. Peres, Christelle Colin, Leyla Shune, Alexandria M Shrewsbury, Rebecca Gonzalez, Douglas W. Sborov, Charlotte B Wagner, Danai Dima, Hamza Hashmi, Mehmet H. Kocoglu, Shebli Atrash, Gary Simmons, Nilesh Kalariya, Christopher J. Ferreri, Aimaz Afrough, Ankit Kansagra, Peter M. Voorhees, Rachid Baz, Jack Khouri, Melissa Alsina, Joseph P. McGuirk, Frederick L. Locke, Krina K. Patel - Journal of Clinical Oncology 2023 被引用: 279

  13. A non-antibiotic-disrupted gut microbiome is associated with clinical responses to CD19-CAR-T cell cancer immunotherapy

    著者: Christoph K. Stein‐Thoeringer, Neeraj Saini, Eli Zamir, Viktoria Blumenberg, Maria‐Luisa Schubert, Uria Mor, Matthias Fante, Sabine Schmidt, Eiko Hayase, Tomo Hayase, Roman Rohrbach, Chia‐Chi Chang, Lauren McDaniel, Ivonne I. Flores, Rogier Gaiser, Matthias Edinger, Daniel Wolff, Martin Heidenreich, Paolo Strati, Ranjit Nair, Dai Chihara, Luis Fayad, Sairah Ahmed, Swaminathan P. Iyer, Raphaël Steiner, Preetesh Jain, Loretta J. Nastoupil, Jason R. Westin, Reetakshi Arora, Michael Wang, Joel G. Turner, Meghan Menges, Melanie J. Hidalgo-Vargas, Kayla Reid, Peter Dreger, Anita Schmitt, Carsten Müller‐Tidow, Frederick L. Locke, Marco L. Davila, Richard E. Champlin, Christopher R. Flowers, Elizabeth J. Shpall, Hendrik Poeck, Sattva S. Neelapu, Michael Schmitt, Marion Subklewe, Michael D. Jain, Robert R. Jenq, Eran Elinav - Nature Medicine 2023 被引用: 226

  14. 5-Year Follow-Up Supports Curative Potential of Axicabtagene Ciloleucel in Refractory Large B-Cell Lymphoma (ZUMA-1)

    著者: Sattva S. Neelapu, Caron A. Jacobson, Armin Ghobadi, David B. Miklos, Lazaros J. Lekakis, Olalekan O. Oluwole, Yi Lin, Ira Braunschweig, Brian T. Hill, John M. Timmerman, Abhinav Deol, Patrick M. Reagan, Patrick J. Stiff, Ian W. Flinn, Umar Farooq, André Goy, Peter A. McSweeney, Javier Muñoz, Tanya Siddiqi, Julio C. Chávez, Alex F. Herrera, Nancy L. Bartlett, Adrian A. Bot, Rhine R. Shen, Jinghui Dong, Kanwarjit Singh, Harry Miao, Jaeyeon Kim, Yan Zheng, Frederick L. Locke - Blood 2023 被引用: 228

  15. Three-Year Follow-Up of KTE-X19 in Patients With Relapsed/Refractory Mantle Cell Lymphoma, Including High-Risk Subgroups, in the ZUMA-2 Study

    著者: Michael Wang, Javier Muñoz, André Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John M. Timmerman, Houston Holmes, Samantha Jaglowski, Ian W. Flinn, Peter A. McSweeney, David B. Miklos, John M. Pagel, Marie José Kersten, Krimo Bouabdallah, Rashmi Khanal, Max S. Topp, Roch Houot, Amer Beitinjaneh, Weimin Peng, Xiang Fang, Rhine R. Shen, Rubina Siddiqi, Ioana Kloos, Patrick M. Reagan - Journal of Clinical Oncology 2022 被引用: 318

  16. The CAR-HEMATOTOX risk-stratifies patients for severe infections and disease progression after CD19 CAR-T in R/R LBCL

    著者: Kai Rejeski, Ariel Perez Perez, Gloria Iacoboni, Olaf Penack, Veit Bücklein, Liv Jentzsch, Dimitrios Mougiakakos, Grace Johnson, Brian Arciola, Cecilia Carpio, Viktoria Blumenberg, Eva Hoster, Lars Bullinger, Frederick L. Locke, Michael von Bergwelt‐Baildon, Andréas Mackensen, Wolfgang Bethge, Pere Barba, Michael D. Jain, Marion Subklewe - Journal for ImmunoTherapy of Cancer 2022 被引用: 191

  17. Real-World Evidence of Axicabtagene Ciloleucel for the Treatment of Large B Cell Lymphoma in the United States

    著者: Caron A. Jacobson, Frederick L. Locke, Long Ma, Julius Asubonteng, Zhen‐Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel‐Angel Perales, Matthew A. Lunning, Megan M. Herr, Brian T. Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Michele Hooper, Jun Kawashima, Hairong Xu, Marcelo C. Pasquini - Transplantation and Cellular Therapy 2022 被引用: 181

  18. Real-world evidence of tisagenlecleucel for pediatric acute lymphoblastic leukemia and non-Hodgkin lymphoma

    著者: Marcelo C. Pasquini, Zhen‐Huan Hu, Kevin J. Curran, Theodore W. Laetsch, Frederick L. Locke, Rayne H. Rouce, Michael A. Pulsipher, Christine L. Phillips, Amy K. Keating, Matthew J. Frigault, Dana Salzberg, Samantha Jaglowski, Joshua Sasine, Joseph Rosenthal, Monalisa Ghosh, Daniel J. Landsburg, Steven Margossian, Paul L. Martin, Manali Kamdar, Peiman Hematti, Sarah Nikiforow, Cameron J. Turtle, Miguel‐Angel Perales, Patricia Steinert, Mary M. Horowitz, Amy Moskop, Lida Pacaud, Lan Yi, Raghav Chawla, Eric Bleickardt, Stephan A. Grupp - Blood Advances 2020 被引用: 434

  19. Tumor immune contexture is a determinant of anti-CD19 CAR T cell efficacy in large B cell lymphoma

    著者: Nathalie Scholler, Régis Perbost, Frederick L. Locke, Michael D. Jain, Sarah Turcan, Corinne Danan, Edmund C. Chang, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Lazaros J. Lekakis, Yi Lin, Armin Ghobadi, Jaeyeon Kim, Justin Chou, Vicki Plaks, Zixing Wang, Allen Xue, Mike Mattie, John M. Rossi, Adrian Bot, Jérôme Galon - Nature Medicine 2022 被引用: 198

  20. How I Treat Cytopenias after CAR T-cell Therapy

    著者: Tania Jain, Timothy S. Olson, Frederick L. Locke - Blood 2023 被引用: 129

  21. Immune reconstitution and associated infections following axicabtagene ciloleucel in relapsed or refractory large B-cell lymphoma

    著者: Jennifer M. Logue, Elisa Zucchetti, Christina A. Bachmeier, Gabriel Krivenko, Victoria S. Larson, Daniel Ninh, Giovanni Grillo, Biwei Cao, Jongphil Kim, Julio C. Chávez, Aliyah Baluch, Farhad Khimani, Aleksandr Lazaryan, Taiga Nishihori, Hien Liu, Javier Pinilla‐Ibarz, Bijal Shah, Rawan Faramand, Anna E. Coghill, Marco L. Davila, Bhagirathbhai Dholaria, Michael D. Jain, Frederick L. Locke - Haematologica 2020 被引用: 271

  22. Tumor interferon signaling and suppressive myeloid cells are associated with CAR T-cell failure in large B-cell lymphoma

    著者: Michael D. Jain, Hua Zhao, Xuefeng Wang, Reginald Atkins, Meghan Menges, Kayla Reid, Kristen Spitler, Rawan Faramand, Christina A. Bachmeier, Erin Dean, Biwei Cao, Julio C. Chávez, Bijal Shah, Aleksandr Lazaryan, Taiga Nishihori, Mohammed Hussaini, Ricardo J. Gonzalez, John E. Mullinax, Paulo C. Rodrı́guez, José R. Conejo-García, Claudio Anasetti, Marco L. Davila, Frederick L. Locke - Blood 2021 被引用: 292

  23. Society for Immunotherapy of Cancer (SITC) clinical practice guideline on immune effector cell-related adverse events

    著者: Marcela V. Maus, S. Alexander, Michael R. Bishop, Jennifer N. Brudno, Colleen Callahan, Marco L. Davila, Claudia Diamonte, Jörg Dietrich, Julie C. Fitzgerald, Matthew J. Frigault, Terry J. Fry, Jennifer Holter‐Chakrabarty, Krishna V. Komanduri, Daniel W Lee, Frederick L. Locke, Shannon L. Maude, Philip L. McCarthy, Elena Mead, Sattva S. Neelapu, Tomas G. Neilan, Bianca Santomasso, Elizabeth J. Shpall, David T. Teachey, Cameron J. Turtle, Tom Whitehead, Stephan A. Grupp - Journal for ImmunoTherapy of Cancer 2020 被引用: 269

  24. Brexucabtagene Autoleucel for Relapsed or Refractory Mantle Cell Lymphoma in Standard-of-Care Practice: Results From the US Lymphoma CAR T Consortium

    著者: Yucai Wang, Preetesh Jain, Frederick L. Locke, Matthew J. Maurer, Matthew J. Frank, Javier Muñoz, Saurabh Dahiya, Amer Beitinjaneh, Miriam T. Jacobs, Joseph P. McGuirk, Julie M. Vose, André Goy, Charalambos Andreadis, Brian T. Hill, Kathleen Dorritie, Olalekan O. Oluwole, Abhinav Deol, Jonas Paludo, Bijal Shah, Trent Wang, Rahul Banerjee, David B. Miklos, Aaron P. Rapoport, Lazaros J. Lekakis, Armin Ghobadi, Sattva S. Neelapu, Yi Lin, Michael Wang, Michael D. Jain - Journal of Clinical Oncology 2023 被引用: 176